Cancer Causes & Control

, Volume 23, Issue 7, pp 1149–1162 | Cite as

Serum 25-hydroxyvitamin D and risk of breast cancer: results of a large population-based case–control study in Mexican women

  • Veronika Fedirko
  • Gabriela Torres-Mejía
  • Carolina Ortega-Olvera
  • Carine Biessy
  • Angelica Angeles-Llerenas
  • Eduardo Lazcano-Ponce
  • Vicente A. Saldaña-Quiroz
  • Isabelle Romieu
Original paper



Epidemiologic studies have suggested that higher levels of circulating vitamin D may reduce breast cancer risk, but no studies have investigated this association among women in developing countries, and very few studies have further investigated this association according to menopausal status.


A population-based case–control study in Mexico with 1,000 incident breast cancer cases aged 35–69 years, enrolled shortly after diagnosis (0–6 days) and frequency-matched to 1,074 controls on age, region, and health care system, was used to assess the association between serum 25-hydroxyvitamin D [25(OH)D] levels with overall, pre- and postmenopausal breast cancer risk. 25(OH)D concentration was measured on a random sub-sample of women (573 cases and 639 matched controls) using a liquid chromatography/tandem mass spectrometry method. Odds ratios (ORs) and 95 % confidence intervals (CIs) were estimated from multivariable conditional logistic regression models.


Serum 25(OH)D concentration (per 10 ng/mL increase) showed a strong inverse association with risk of breast cancer among all (p trend = 0.001), pre- (p trend = 0.006) and postmenopausal women (p trend = 0.0001). Compared with a predefined lower concentration of 25(OH)D (<20 ng/mL), higher levels (>30 ng/mL) were associated with lower overall (OR = 0.53, 95 % CI: 0.28–1.00; p trend = 0.002), pre- (OR = 0.60, 95 % CI: 0.16–2.17; p trend = 0.07) and postmenopausal (OR = 0.37, 95 % CI: 0.16–0.82; p trend = 0.004) breast cancer risk.


The results of this large population-based case–control study indicate an inverse association between circulating vitamin D levels and breast cancer risk among pre- and postmenopausal Mexican women.


Breast neoplasms Vitamin D 25-Hydroxy vitamin D Case–control studies Mexico 



We would like to thank CONACyT for the financial support provided for this work and all physicians responsible for the project in the different participating hospitals: Dr. Germán Castelazo (IMSS, Hospital de la Raza, Ciudad de México, DF), Dr. Sinhué Barroso Bravo (IMSS, Hospital siglo XXI, Ciudad de México, DF), Dr. Fernando Mainero Ratchelous (IMSS, Hospital de Gineco-Obstetricia No 4. “Luis Castelaco Ayala”, Ciudad de México, DF), Dr. Hernando Miranda Hernández, SS, Hospital General de México, Ciudad de México, DF), Dr. Joaquín Zarco Méndez (ISSSTE, Hospital 20 de Noviembre, Ciudad de México, DF), Dr. Edelmiro Pérez Rodríguez (Hospital Universitario, Monterrey, Nuevo León), Dr. Jesús Pablo Esparza Cano (IMSS, Hospital No. 23 de Ginecología, Monterrey, Nuevo León), Dr. Heriberto Fabela (IMSS, Hospital No. 23 de Ginecología, Monterrey, Nuevo León), Dr. José Pulido Rodríguez (SS, Hospital Metropolitano Dr. “Bernardo Sepulveda”, Monterrey, Nuevo León), Dr. Manuel de Jesús García Solis (SS, Hospital Metropolitano Dr. “Bernardo Sepulveda”, Monterrey, Nuevo León), Dr. Fausto Hernández Morales (ISSSTE, Hospital General, Veracruz, Veracruz), Dr. Pedro Coronel Brizio (SS, Centro Estatal de Cancerología “Dr. Miguel Dorantes Mesa”, Xalapa, Veracruz), Dr. Vicente A. Saldaňa Quiroz (IMSS, Hospital Gineco-Pediatría No 71, Veracruz, Veracruz), M. C. Teresa Shamah Levy, INSP, Cuernavaca Mor. This work was supported by Consejo Nacional de Ciencia y Tecnologia CONACyT 2002-C01-7462 and the National Institutes of Health (1U54CA13238).

Conflict of interest

None declared.

Supplementary material

10552_2012_9984_MOESM1_ESM.doc (158 kb)
Supplementary material 1 (DOC 158 kb)


  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) GLOBOCAN v1.2, Cancer incidence and mortality worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer. Available from:, accessed on 06/07/2011
  2. 2.
    WCRF/AICR (2007) World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. AICR, Washington, DCGoogle Scholar
  3. 3.
    Gorham ED, Garland CF, Garland FC (1989) Acid haze air pollution and breast and colon cancer mortality in 20 Canadian cities. Can J Public Health 80:96–100PubMedGoogle Scholar
  4. 4.
    Garland FC, Garland CF, Gorham ED, Young JF (1990) Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med 19:614–622PubMedCrossRefGoogle Scholar
  5. 5.
    Gorham ED, Garland FC, Garland CF (1990) Sunlight and breast cancer incidence in the USSR. Int J Epidemiol 19:820–824PubMedCrossRefGoogle Scholar
  6. 6.
    Deeb KK, Trump DL, Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7:684–700PubMedCrossRefGoogle Scholar
  7. 7.
    James SY, Mackay AG, Colston KW (1996) Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol 58:395–401PubMedCrossRefGoogle Scholar
  8. 8.
    Matthews D, LaPorta E, Zinser GM, Narvaez CJ, Welsh J (2010) Genomic vitamin D signaling in breast cancer: insights from animal models and human cells. J Steroid Biochem Mol Biol 121:362–367PubMedCrossRefGoogle Scholar
  9. 9.
    Krishnan AV, Feldman D (2011) Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 51:311–336PubMedCrossRefGoogle Scholar
  10. 10.
    Welsh J (2004) Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr 80:1721S–1724SPubMedGoogle Scholar
  11. 11.
    Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW, Coombes RC (1988) Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab 67:607–613PubMedCrossRefGoogle Scholar
  12. 12.
    Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, Milanezi F, Paredes J, Costa JL, Schmitt F (2010) Alterations in vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer 10:483PubMedCrossRefGoogle Scholar
  13. 13.
    Prentice A, Goldberg GR, Schoenmakers I (2008) Vitamin D across the lifecycle: physiology and biomarkers. Am J Clin Nutr 88:500S–506SPubMedGoogle Scholar
  14. 14.
    Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, Chang-Claude J (2008) Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer–results of a large case-control study. Carcinogenesis 29:93–99PubMedCrossRefGoogle Scholar
  15. 15.
    Abbas S, Chang-Claude J, Linseisen J (2009) Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case-control study. Int J Cancer 124:250–255PubMedCrossRefGoogle Scholar
  16. 16.
    Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG, Colston KW (2005) Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 41:1164–1169PubMedCrossRefGoogle Scholar
  17. 17.
    Crew KD, Gammon MD, Steck SE, Hershman DL, Cremers S, Dworakowski E, Shane E, Terry MB, Desai M, Teitelbaum SL et al (2009) Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res 2:598–604CrossRefGoogle Scholar
  18. 18.
    Rejnmark L, Tietze A, Vestergaard P, Buhl L, Lehbrink M, Heickendorff L, Mosekilde L (2009) Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev 18:2655–2660PubMedCrossRefGoogle Scholar
  19. 19.
    Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE (2005) Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 14:1991–1997PubMedCrossRefGoogle Scholar
  20. 20.
    Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, Rossouw J, Lane D, O’Sullivan MJ, Yasmeen S et al (2008) Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 100:1581–1591PubMedCrossRefGoogle Scholar
  21. 21.
    McCullough ML, Stevens VL, Patel R, Jacobs EJ, Bain EB, Horst RL, Gapstur SM, Thun MJ, Calle EE (2009) Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res 11:28CrossRefGoogle Scholar
  22. 22.
    Almquist M, Bondeson AG, Bondeson L, Malm J, Manjer J (2010) Serum levels of vitamin D, PTH and calcium and breast cancer risk-a prospective nested case-control study. Int J Cancer 127:2159–2168PubMedCrossRefGoogle Scholar
  23. 23.
    Freedman DM, Chang SC, Falk RT, Purdue MP, Huang WY, McCarty CA, Hollis BW, Graubard BI, Berg CD, Ziegler RG (2008) Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 17:889–894PubMedCrossRefGoogle Scholar
  24. 24.
    Engel P, Fagherazzi G, Boutten A, Dupre T, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F (2010) Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 19:2341–2350Google Scholar
  25. 25.
    Freedman DM, Looker AC, Chang SC, Graubard BI (2007) Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 99:1594–1602PubMedCrossRefGoogle Scholar
  26. 26.
    Eliassen AH, Spiegelman D, Hollis BW, Horst RL, Willett WC, Hankinson SE (2011) Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses’ Health Study II. Breast Cancer Res 13:R50PubMedCrossRefGoogle Scholar
  27. 27.
    Mohr SB, Gorham ED, Alcaraz JE, Kane CJ, Macera CA, Parsons JK, Wingard DL, Garland CF (2011) Serum 25-hydroxyvitamin D and prevention of breast cancer: pooled analysis. Anticancer Res 31:2939–2948PubMedGoogle Scholar
  28. 28.
    Beasley JM, Coronado GD, Livaudais J, Angeles-Llerenas A, Ortega-Olvera C, Romieu I, Lazcano-Ponce E, Torres-Mejia G (2010) Alcohol and risk of breast cancer in Mexican women. Cancer Causes Control 21:863–870PubMedCrossRefGoogle Scholar
  29. 29.
    Angeles-Llerenas A, Ortega-Olvera C, Perez-Rodriguez E, Esparza-Cano JP, Lazcano-Ponce E, Romieu I, Torres-Mejia G (2010) Moderate physical activity and breast cancer risk: the effect of menopausal status. Cancer Causes Control 21:577–586PubMedCrossRefGoogle Scholar
  30. 30.
    Fejerman L, Romieu I, John EM, Lazcano-Ponce E, Huntsman S, Beckman KB, Perez-Stable EJ, Gonzalez Burchard E, Ziv E, Torres-Mejia G (2010) European ancestry is positively associated with breast cancer risk in Mexican women. Cancer Epidemiol Biomarkers Prev 19:1074–1082PubMedCrossRefGoogle Scholar
  31. 31.
    Hernandez-Avila M, Romieu I, Parra S, Hernandez-Avila J, Madrigal H, Willett W (1998) Validity and reproducibility of a food frequency questionnaire to assess dietary intake of women living in Mexico City. Salud Publica Mex 40:133–140PubMedCrossRefGoogle Scholar
  32. 32.
    Herrmann M, Harwood T, Gaston-Parry O, Kouzios D, Wong T, Lih A, Jimenez M, Janu M, Seibel MJ (2010) A new quantitative LC tandem mass spectrometry assay for serum 25-hydroxy vitamin D. Steroids 75:1106–1112PubMedCrossRefGoogle Scholar
  33. 33.
    Roth HJ, Schmidt-Gayk H, Weber H, Niederau C (2008) Accuracy and clinical implications of seven 25-hydroxyvitamin D methods compared with liquid chromatography-tandem mass spectrometry as a reference. Ann Clin Biochem 45:153–159PubMedCrossRefGoogle Scholar
  34. 34.
    Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96. doi: 10.1210/jc.2011-0385
  35. 35.
    Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A (2006) Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296:2832–2838PubMedCrossRefGoogle Scholar
  36. 36.
    Jenab M, Bueno-de-Mesquita HB, Ferrari P, van Duijnhoven FJ, Norat T, Pischon T, Jansen EH, Slimani N, Byrnes G, Rinaldi S et al (2010) Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. BMJ 340:b5500PubMedCrossRefGoogle Scholar
  37. 37.
    Xie SP, Pirianov G, Colston KW (1999) Vitamin D analogues suppress IGF-I signalling and promote apoptosis in breast cancer cells. Eur J Cancer 35:1717–1723PubMedCrossRefGoogle Scholar
  38. 38.
    Vink-van Wijngaarden T, Pols HA, Buurman CJ, Birkenhager JC, van Leeuwen JP (1996) Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089. Eur J Cancer 32A:842–848PubMedCrossRefGoogle Scholar
  39. 39.
    Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H (2010) Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat 121:469–477PubMedCrossRefGoogle Scholar
  40. 40.
    Flores M, Sánchez Romero LM, Macías N, Lozada A, Díaz E, Barquera S (2011) Concentraciones séricas de vitamina D en niños, adolescentes y adultos mexicanos. Resultados de la ENSANUT 2006: Instituto Nacional de Salud PúblicaGoogle Scholar
  41. 41.
    Elizondo-Alanís JR, Espinoza-Zamora JR, Zayas-Jaime SJ (2006) Serum levels of vitamin D in healthy postmenopausal women at 4 cities in Mexico. Rev Metab Óseo Miner 4:389–398Google Scholar
  42. 42.
    Segaert S, Garmyn M, Degreef H, Bouillon R (1997) Retinoic acid modulates the anti-proliferative effect of 1,25-dihydroxyvitamin D3 in cultured human epidermal keratinocytes. J Invest Dermatol 109:46–54PubMedCrossRefGoogle Scholar
  43. 43.
    Oberg F, Botling J, Nilsson K (1993) Functional antagonism between vitamin D3 and retinoic acid in the regulation of CD14 and CD23 expression during monocytic differentiation of U-937 cells. J Immunol 150:3487–3495PubMedGoogle Scholar
  44. 44.
    Rohde CM, DeLuca HF (2005) All-trans retinoic acid antagonizes the action of calciferol and its active metabolite, 1,25-dihydroxycholecalciferol, in rats. J Nutr 135:1647–1652PubMedGoogle Scholar
  45. 45.
    Rohde CM, Manatt M, Clagett-Dame M, DeLuca HF (1999) Vitamin A antagonizes the action of vitamin D in rats. J Nutr 129:2246–2250PubMedGoogle Scholar
  46. 46.
    Houghton LA, Vieth R (2006) The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr 84:694–697PubMedGoogle Scholar
  47. 47.
    Mejia-Rodriguez F, Sotres-Alvarez D, Neufeld LM, Garcia-Guerra A, Hotz C (2007) Use of nutritional supplements among Mexican women and the estimated impact on dietary intakes below the EAR and above the UL. J Am Coll Nutr 26:16–23PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Veronika Fedirko
    • 1
  • Gabriela Torres-Mejía
    • 2
  • Carolina Ortega-Olvera
    • 2
  • Carine Biessy
    • 1
  • Angelica Angeles-Llerenas
    • 2
  • Eduardo Lazcano-Ponce
    • 2
  • Vicente A. Saldaña-Quiroz
    • 3
  • Isabelle Romieu
    • 1
    • 2
  1. 1.International Agency for Research on Cancer (IARC)Lyon Cedex 08France
  2. 2.Centro de Investigaciones en Salud PoblacionalNational Institute of Public Health/Instituto Nacional de Salud PúblicaCuernavaca MorelosMéxico
  3. 3.Hospital de Gineco-Pediatría No. 71 “Lic. Benito Coquet Lagunes”Instituto Mexicano del Seguro Social (IMSS)VeracruzMéxico

Personalised recommendations